Panbela Therapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 8

Employees

  • Stock Symbol
  • PBLA

Stock Symbol

  • Investments
  • 2

Panbela Therapeutics General Information

Description

Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.

Contact Information

Website
www.panbela.com
Formerly Known As
Sun BioPharma, Cimarron Medical, Cimarron Software
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 712 Vista Boulevard
  • Suite 305
  • Waconia, MN 55387
  • United States
+1 (952)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Stock Exchange
OTCM
Vertical(s)
Corporate Office
  • 712 Vista Boulevard
  • Suite 305
  • Waconia, MN 55387
  • United States
+1 (952)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Panbela Therapeutics Stock Performance

As of 09-Nov-2026, Panbela Therapeutics’s current market cap is $971.00.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.01 $971.00 3.25K

Panbela Therapeutics Financials Summary

As of 30-Sep-2024, Panbela Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 5,861 10,552 8,227 9,139
Revenue 0 0 0 0
EBITDA (27,444) (25,255) (34,775) (10,612)
Net Income (27,913) (25,263) (34,933) (10,135)
Total Assets 5,168 11,802 4,978 12,872
Total Debt 6,394 5,194 6,844 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Panbela Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Panbela Therapeutics‘s full profile, request access.

Request a free trial

Panbela Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatm
Drug Discovery
Waconia, MN
8 As of 2024

Boston, MA
 

Fort Collins, CO
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Panbela Therapeutics Competitors (61)

One of Panbela Therapeutics’s 61 competitors is Aura Biosciences, a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Formerly VC-backed Boston, MA
Statera Biopharma Formerly VC-backed Fort Collins, CO
Biodexa Pharmaceuticals Formerly PE-Backed Cardiff, United Kingdom
MannKind Formerly VC-backed Danbury, CT
Allarity Therapeutics Corporation Tarpon Springs, FL
You’re viewing 5 of 61 competitors. Get the full list »

Panbela Therapeutics Patents

Panbela Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3164914-A1 Dosing regimens and methods for treating cancer Pending 20-Jan-2020
US-20230064990-A1 Dosing regimens and methods for treating cancer Inactive 20-Jan-2020
WO-2021150559-A1 Dosing regimens and methods for treating cancer Inactive 20-Jan-2020
AU-2019213664-A1 Methods for producing (6s,15s)-3,8,13,18-tetraazaicosane-6,15-diol Active 30-Jan-2018
AU-2019213664-B2 Methods for producing (6s,15s)-3,8,13,18-tetraazaicosane-6,15-diol Inactive 30-Jan-2018 C07C213/08
To view Panbela Therapeutics’s complete patent history, request access »

Panbela Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Panbela Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Panbela Therapeutics‘s full profile, request access.

Request a free trial

Panbela Therapeutics Acquisitions (2)

Panbela Therapeutics’s most recent deal was a Merger/Acquisition with Cancer Prevention Pharmaceuticals for . The deal was made on 15-Jun-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cancer Prevention Pharmaceuticals 15-Jun-2022 Merger/Acquisition Drug Discovery
Cimarron Software 04-Sep-2015 Merger/Acquisition Other Healthcare Technology Systems
To view Panbela Therapeutics’s complete acquisitions history, request access »

Panbela Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Panbela Therapeutics’s complete esg history, request access »

Panbela Therapeutics FAQs

  • When was Panbela Therapeutics founded?

    Panbela Therapeutics was founded in 2011.

  • Where is Panbela Therapeutics headquartered?

    Panbela Therapeutics is headquartered in Waconia, MN.

  • What is the size of Panbela Therapeutics?

    Panbela Therapeutics has 8 total employees.

  • What industry is Panbela Therapeutics in?

    Panbela Therapeutics’s primary industry is Drug Discovery.

  • Is Panbela Therapeutics a private or public company?

    Panbela Therapeutics is a Public company.

  • What is Panbela Therapeutics’s stock symbol?

    The ticker symbol for Panbela Therapeutics is PBLA.

  • What is the current market cap of Panbela Therapeutics?

    The current market capitalization of Panbela Therapeutics is $971.00.

  • Who are Panbela Therapeutics’s competitors?

    Aura Biosciences, Statera Biopharma, Biodexa Pharmaceuticals, MannKind, and Allarity Therapeutics are some of the 61 competitors of Panbela Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process